Meeting
2023 ASCO Annual Meeting
Real-world outcomes with novel therapies in R/R DLBCL.
Authors
Jennifer Leigh Crombie
Dana-Farber Cancer Institute, Boston, MA
Jennifer Leigh Crombie , Monika P. Jun , Tongsheng Wang , Alex Mutebi , Anthony Wang , Anindit Chibber , Rajesh Kamalakar , Jon Ukropec , Julie Blædel , Anupama Kalsekar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7552)
DOI
10.1200/JCO.2023.41.16_suppl.7552
Abstract #
7552
Poster Bd #
103
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.
First Author: Umberto Vitolo
Poster
2020 ASCO Virtual Scientific Program
RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
First Author: Grzegorz S. Nowakowski
Poster
2019 ASCO Annual Meeting
Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US lymphoma CAR-T consortium.
First Author: Jay Y. Spiegel
Poster
2024 ASCO Annual Meeting
Carfilzomib plus rituximab, ifosfamide, carboplatin and etoposide (C-RICE) led to higher response, OS, and PFS in patients with transplant-eligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
First Author: Mody Amin